Ask AI
Managing Anemia in LR MDS

CE / CME

Novel Therapeutic Approaches and Personalized Strategies for Managing Anemia in LR-MDS

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.25 Medical Knowledge MOC points

Released: July 15, 2025

Expiration: January 14, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case



  • A 64-yr-old woman with increasing fatigue over the past 9 mo

  • She has isolated normocytic anemia with hemoglobin 8.6 g/dL

  • A complete anemia workup revealed mild erythroblastic dysplasia with 8% ring sideroblasts and an SF3B1 mutation, non del(5q)

  • She is found to have an IPSS-R score of 2 and EPO level of 390 U/mL

  • RBC transfusion dependent: 3 RBC units/8 wk

In your clinical practice, how would you manage this patient’s anemia?

2.

Your patient with RS+ LR-MDS has been receiving luspatercept 1.33 mg/kg Q3W but is experiencing fatigue and is transfusion dependent (4 units RBC/8 wk) after 8 wk of treatment. Which of the following would be the next best step for this patient?

3.

Patient Case



  • A 70-yr-old man presents with anemia

  • A complete workup reveals low-risk MDS (IPSS: 0.5; IPSS-R: 2) with mutated DNMT3A and SF3B1, non del(5q)

  • Anemia managed with an ESA for >18 mo

  • Your patient complains of fatigue and has worsening anemia 2 yr later

    • Hb 7 g/dL, WBC 6.1, platelets 270,000/mm3

    • MDS-RS-MLD with no increase in the bone marrow blasts

    • Ring sideroblasts: 55%

    • Cytogenetics are still normal



  • He receives an average of 6 units RBC/8 wk

In your clinical practice, how would you manage this patient’s anemia?

4.

Working with colleagues on the healthcare team, how would you manage the first occurrence of grade 3 neutropenia in a patient with LR-MDS receiving imetelstat?